Colleen Kusy
Stock Analyst at Baird
(1.52)
# 3,522
Out of 5,106 analysts
53
Total ratings
39.13%
Success rate
-7.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Outperform | $112 → $158 | $104.72 | +50.88% | 3 | Nov 18, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $14 → $34 | $42.11 | -19.26% | 1 | Nov 11, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $50 → $52 | $25.23 | +106.10% | 13 | Oct 31, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $17 → $24 | $14.56 | +64.84% | 5 | Oct 3, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $9 | $3.00 | +200.00% | 1 | Aug 15, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $16.86 | +208.42% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $3.79 | +58.31% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $20.73 | +97.78% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $1.35 | +344.44% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $33.62 | +93.34% | 2 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $100 → $75 | $28.35 | +164.55% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $27 → $25 | $9.38 | +166.52% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $6.95 | +2,921.58% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.20 | +1,445.45% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $3.81 | +5,936.75% | 1 | Nov 2, 2021 |
Nuvalent
Nov 18, 2025
Maintains: Outperform
Price Target: $112 → $158
Current: $104.72
Upside: +50.88%
Cogent Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $14 → $34
Current: $42.11
Upside: -19.26%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Outperform
Price Target: $50 → $52
Current: $25.23
Upside: +106.10%
Ocular Therapeutix
Oct 3, 2025
Maintains: Outperform
Price Target: $17 → $24
Current: $14.56
Upside: +64.84%
Climb Bio
Aug 15, 2025
Initiates: Outperform
Price Target: $9
Current: $3.00
Upside: +200.00%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $16.86
Upside: +208.42%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $3.79
Upside: +58.31%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $20.73
Upside: +97.78%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.35
Upside: +344.44%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $33.62
Upside: +93.34%
Aug 14, 2024
Maintains: Neutral
Price Target: $100 → $75
Current: $28.35
Upside: +164.55%
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $9.38
Upside: +166.52%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $6.95
Upside: +2,921.58%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.20
Upside: +1,445.45%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $3.81
Upside: +5,936.75%